In data from a pivotal phase 3 trial, EF-14, the addition of Optune to standard of care chemotherapy (temozolomide) significantly improved overall survival at two and five years in a sample of ...

Data show a three-month improvement in overall and progression-free survival for patients using Optune plus standard therapy temozolomide, compared to patients using temozolomide on its own.

Tumor Treating Fields therapy demonstrates increased overall survival in patients with unresectable pancreatic cancer. The ...

After obtaining positive results that showed significant extension of progression-free and overall survival in newly diagnosed GBM patients treated with Optune in combination with TMZ versus TMZ ...

It said it recommended against the use of Optune "because there was insufficient evidence of its clinical effectiveness in terms of improvement in overall survival and progression-free survival to ...

The company said 2024 growth was primarily driven by its launch in France and improved approval rates in the U.S., which are now reflected in ...

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 ...